top of page
brainwaves-logo-horizontal.png

Nondilutive Funding for Biotech Founders That Isn't an SBIR

Writer: Melanie Das
Melanie Das
10 minutes ago
4 min read


A compass and map representing the process of navigating alternative funding opportunities for biotech startups beyond SBIR grants.

Nondilutive funding is synonymous with grants and when we’re talking grants for startups we’re usually talking about SBIR. But if there is anything we learned from this past year’s mess is that we need to talk about non-SBIR grants. 


Why side-door money behaves differently

We’re all pretty familiar with how a SBIR works. It is a grant. The company keeps title to its inventions under the Bayh-Dole Act, nobody takes equity, nobody takes a royalty, and the government allows up to 40 percent in indirect costs on a Phase I when you have no negotiated rate (as of now), plus a fee. Just know that not every non-dilutive dollar is alike.


But when you’re looking at other options make sure to read through the “terms and conditions”. A disease foundation holds philanthropic money that it has promised donors will reach patients, so it wants evidence of progress on its own timeline and, frequently, a return it can recycle into the next project. A federal agency outside the grant system is buying a capability, so it writes a contract and pays only against delivery (more on that later). 


The obvious objection is that these terms make other nondilutive funds not as pretty as SBIR, and for some companies this is true. But there are advantages too. For example the Michael J. Fox Foundation will fund IND-enabling studies up to $5 million over two years and reviews a pre-proposal within three weeks, whereas an NIH application takes most of a year to reach an award. Some other funds also bring you connections, training, and a whole slew of resources to boot. And yes, of course non-SBIR funds is always nice to have when say, there’s a 6 month stoppage of SBIR grants.


Six examples of non-SBIR funds


Disease foundations that fund companies. Several large patient foundations run programs aimed squarely at industry. The terms vary, and that variation is the reason to read closely.


These are three foundations with three different ideas of a fair return. Taken together, they show why the term sheet deserves as much attention as the science section.


NIH programs that aren't SBIR but welcome companies. Listen to me startups. Just because NIH programs list for-profits as eligible applicants alongside universities does NOT mean you are competitive. Don’t let anyone tell you to start applying for R01s and R21s willy nilly. These are NOT for you (most of the time) and whoever told you that better have a good reason why you have a good chance of winning these. But NIH programs are not all off the table. The clearest example for neuroscience founders is the Blueprint Neurotherapeutics Network. Its biologics track, PAR-24-293, is a phased cooperative agreement (a UG3 that converts to a UH3 when milestones are met). It is open to small businesses and larger for-profits. Alongside the award, it offers in-kind access to BPN contract research organizations for manufacturing, nonclinical and early clinical work, with NIH covering those costs, plus consultants at no charge. Institutions keep their existing IP and are assigned rights to new IP developed in the program. There is also a companion small-molecule track.


Commercialization programs built on top of an SBIR. Some programs exist to carry SBIR-funded technology the rest of the way. The National Commercialization and Translation Institute, a two-year, $20 million NSF pilot led by the University of Central Florida, will make milestone-based awards of $1 million to $3.75 million to six to eight companies, with mentors, checkpoint reviews and investor introductions attached. It is open only to companies holding an NSF SBIR or STTR Phase II or IIB award that is active or completed within the last two years. 


Biodefense and health security. BARDA, part of HHS, funds medical countermeasures (the drugs, vaccines, diagnostics and devices used in emergencies). Its DRIVe EZ-BAA is a standing solicitation listed as open through October 18, 2027, with areas of interest that have included Lab at Home, Digital MCMs, ReDIRECT and host-based diagnostics. These are contracts, so BARDA is buying progress toward a capability rather than supporting research for its own sake. 


ARPA-H's rolling openings. ARPA-H's four Mission Office openings accept submissions on a rolling basis, and each requires a short Solution Summary and written feedback from ARPA-H before a full proposal. ARPA-H funds mainly through Other Transactions, and Bayh-Dole does not apply to Other Transactions, so your IP position is whatever you negotiate. They just started rolling out SBIR solicitations this year on specific topics so be on the lookout for those as well.


CDMRP. The Defense Department's Congressionally Directed Medical Research Programs put $1.27 billion across 34 programs into the FY26 cycle, and small businesses compete alongside universities. The FY27 cycle depends on full-year appropriations, which do not exist yet. The government is running on a stopgap measure through December 11. 


Four questions to ask before you apply


  1. First, who owns the IP? Under a grant, Bayh-Dole gives you a statutory default. Under an Other Transaction or a foundation agreement, ownership is whatever the agreement says, and the agreement is drafted by the funder.

  2. Second, what is the indirect cap? MJFF's 10 percent for companies and NIH's 40 percent on a Phase I produce very different budgets for the same work. Make sure your budget meets the funder's requirements.

  3. Third, is a match required? Breakthrough T1D asks you to put in at least as much as you request. That is a reasonable term for a company with investors but it does rule out companies without them. 

  4. Fourth, what does the funder get back? Revenue share, royalty, equity, convertible note, or nothing. None of these is disqualifying. Each one belongs in your cap table conversation before it belongs in your science conversation.




 
 
 

Comments


brainwaves-logo-horizontal.png

Helping science and health organizations secure funding to accelerate their impact.

2261 Market Street PMB 86866,

San Francisco, CA 94114

© 2026 Brainwaves Consulting, LLC

bottom of page